GWP42003-P

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Seizure in Participants With Tuberous Sclerosis Complex

Conditions

Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome

Trial Timeline

May 19, 2021 → Jan 28, 2025

NCT ID

NCT04485104

About GWP42003-P

GWP42003-P is a phase 3 stage product being developed by Jazz Pharmaceuticals for Seizure in Participants With Tuberous Sclerosis Complex. The current trial status is terminated. This product is registered under clinical trial identifier NCT04485104. Target conditions include Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome.

What happened to similar drugs?

14 of 20 similar drugs in Seizure in Participants With Tuberous Sclerosis Complex were approved

Approved (14) Terminated (5) Active (6)

✅Adjunctive Zonisamide + Replacement with ZonisamideEisaiApproved

✅PerampanelEisaiApproved

✅Eslicarbazepine acetate + Eslicarbazepine AcetateSumitomo PharmaApproved

✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved

✅OxcarbazepineNovartisApproved

✅PregabalinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04485104	Phase 3	Terminated	May 19, 2021	Jan 28, 2025	Seizure in Participants With Tuberous Sclerosis Complex
NCT04133480	Approved	Withdrawn	Oct 1, 2020	Dec 1, 2021	Lennox-Gastaut Syndrome
NCT04252586	Phase 3	Terminated	Feb 28, 2020	Jun 9, 2021	Rett Syndrome
NCT02954887	Phase 3	Completed	May 12, 2017	Jun 13, 2019	Infantile Spasms
NCT02953548	Phase 3	Completed	Apr 24, 2017	May 7, 2018	Infantile Spasms
NCT02607904	Phase 2	Completed	Dec 15, 2016	May 27, 2019	Epilepsy
NCT02544750	Phase 3	Completed	Aug 31, 2016	Jun 11, 2021	Tuberous Sclerosis Complex

Competing Products

20 competing products in Seizure in Participants With Tuberous Sclerosis Complex

See all competitors

Product	Company	Stage	Hype Score
E2007	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
perampanel + perampanel + perampanel + Placebo	Eisai	Phase 3	40
perampanel	Eisai	Phase 2	35
Perampanel	Eisai	Pre-clinical	26
Perampanel + Placebo comparator	Eisai	Phase 3	40
Zonisamide + Placebo	Eisai	Phase 3	40
zonisamide	Eisai	Pre-clinical	26
E2007 (perampanel) + E2007 (perampanel) + Placebo	Eisai	Phase 3	40
Perampanel + Placebo	Eisai	Phase 3	40
E2007 (perampanel) + E2007 (perampanel) + Placebo	Eisai	Phase 3	40
Adjunctive Zonisamide + Replacement with Zonisamide	Eisai	Approved	43
Fycompa	Eisai	Pre-clinical	26
Zonisamide + Placebo	Eisai	Phase 3	40
Fycompa	Eisai	Pre-clinical	26
Rufinamide	Eisai	Phase 3	32
Eslicarbazepine Acetate tablets	Eisai	Pre-clinical	26
Perampanel	Eisai	Pre-clinical	26
Perampanel	Eisai	Pre-clinical	26
Perampanel	Eisai	Approved	43